Bibliografia

  1. Kelber, O ., F . Gaedcke, B . Steinhoff and H . Winterhoff “Ethanol in herbal medicinal products for children .” PharmInd, 2008 . 70(9): 1124–7 .
  2. Pilichiewicz, A . N ., M . Horowitz, G . J . Holtmann, N . J . Talley and C . Feinle-Bisset "Relationship between symptoms and dietary patterns in patients with functional dyspepsia ." Clin Gastroenterol Hepatol, 2009 . 7(3): 317-22 .
  3. von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .
  4. Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis .” Mol Med, 2015 . 21(1): 1011–1024 .
  5. Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017 . 83(14/15): 1130–1140 .
  6. Adarsh, M . B ., S . K . Sharma, K . K . Prasad, V . Dhir, S . Singh and S . K . Sinha " Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis ." JGH Open, 2019 . 3(3): 206-209 .
  7. Allam, S ., D . Krueger, I . E . Demir, G . Ceyhan, F . Zeller and M . Schemann “Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine .” Phytomedicine, 2015 . 22(12): 1063–1070 .
  8. Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target .” Dig Dis, 2017 . 35 (Suppl 1): 18–24 .
  9. Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomed, 2006. 13 SV 2-11
  10. Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy ." Phytomedicine, 2006. 13 SV 2-11 .
  11. Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006 . 13 (Suppl 5): 67–74 .
  12. Angelicae radix, ESCOP monographs 2009.
  13. Anisi Fructus, ESCOP monographs 2014 .
  14. Annibale. B ., G . Esposito and E . Lahner " A current clinical overview of atrophic gastritis ." Expert Rev Gastroenterol Hepatol, 2020 . 14(2): 93-102 .
  15. Balaban, C . D . and B . J . Yates "What is nausea? A historical analysis of changing views ." Auton Neurosci, 2017 . 202: 5-17 .
  16. Berg, L . K ., E . Fagerli, M . Martinussen, A . O . Myhre, J . Florholmen and R . Goll "Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test ." Scand J Gastroenterol, 2013 . 48(8): 936-43 .
  17. Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005 . 20(3): 332-9 .
  18. Bleimann, H ., R . Hartmann "Therapy of Gastrointestinal Functional Disorders with Iberogast® ." Der Kassenarzt, 1983; 23:52-59 .
  19. Boeckxstaens, G ., M . Camilleri, D . Sifrim, L . A . Houghton, S . Elsenbruch, G . Lindberg, F . Azpiroz and H . P . Parkman "Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation ." Gastroenterology, 2016 . 150: 1292-1304 .
  20. Boland, M . "Human digestion - a processing perspective ." J Sci Food Agric, 2016 . 96: 2275-283 .
  21. Bonaterra, G . A ., O . Kelber, D . Weiser and R . Kinscherf “Mechanisms of the antiproliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro .” Phytomedicine, 2013 . 20(8–9): 691–698 .
  22. Bonaterra, G ., R . Kinscherf, O . Kelber, D . Weiser and J . Metz “Antiinflammatorische und antiproliferative Wirkung von Iberogast® in vitro .” Z Gastroenterol, 2008 . 46(09): P352 .
  23. Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis .” Neurogastroenterology & Motility, 2009 . 21(6): 632–e625 .
  24. Bredenoord, A . J . and A . J . P . Smout "Physiologic and pathologic belching ." Clin Gastroenterol Hepatol, 2007 . 5(7): 772-5 .
  25. Bremer, W ., F . Fischer and K . Nicolay "Gastrointestinal Illnesses - Therapy with Iberogast® " Z. Allg. Med., 1983 . 59: 1706-1709 .
  26. Brückel, M . H ., W . Gisevius "Iberis Amara Helps in Cases of Functional Stomach Complaints ." Ärztl. Praxis, 1984 . 36: 494 .
  27. Brun, R . and B . Kuo “Functional dyspepsia .” Therap Adv Gastroenterol, 2010 . 3(3):145–164 .
  28. Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .
  29. Buchert, D . “Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie .” Z Phytother, 1994 . 15: 24-25 .
  30. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rabbit .” 2003 . Sequani Study no: VEB0003 .
  31. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rat .” 2003 . Sequani Study no: VEB0006 [Module 4 .2 .3 .5 .1 .3] .
  32. Burns, L . M . “Oral (gavage) developmental toxicity study in the rabbit .” 2003 . Sequani Study no: VEB0004 .
  33. Burns, L . M . “Oral (gavage) developmental toxicity study in the rat .” 2003 . Sequani Study no: VEB0008 [Module 4 .2 .3 .5 .1 .2] .
  34. Burns, L . M . “Oral (gavage) fertility and early embryonic development study in the rat .” 2003 . Sequani Study no: VEB0007 [Module 4 .2 .3 .5 .1 .4] .
  35. Burns, L . M . “Oral (gavage) fertility and general reproductive performance dose ranging study in the rat .” 2003 . Sequani Study no: VEB0005 [Module 4 .2 .3 .5 .1 .1] .
  36. Burns, L . M . “Oral (gavage) maximum tolerated dose (MTD) study in the rabbit .” 2003 . Sequani Study no: VEB0002 .
  37. Burns, L . M . “Oral (gavage) pre- and post-natal developmental toxicity study in the rat .” 2003 . Study no: VEB0009 [Module 4 .2 .3 .5 .3 .1] .
  38. Burri, E ., E . Barba, J . W . Huaman, D . Cisternas, A . Accarino, A . Soldevilla, J . R . Malagelada, and F . Azpiroz "Mechanisms of postprandial abdominal bloating and distension in functional dyspepsia ." Gut, 2014 . 63(3): 395-400 .
  39. Bustos, M ., R . Venkataramanan and Steve Caritis "Nausea and vomiting of pregnancy - What's new? " Auton Neurosci, 2017. 202: 62-72 .
  40. Bytzer, P . and N . J . Talley “Dyspepsia .” Ann Intern Med, 2001 . 134(9 Pt 2): 815–822 .
  41. Camilleri, M ., B . Coulie and J . F . Tack “Visceral hypersensitivity: facts, speculations, and challenges .” Gut, 2001 . 48(1): 125–131 .
  42. Carvalho, R . V . B ., S . L . S . Lorena, J . R . de Souza Almeida and M . A . Mesquita "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients ." Dig Dis Sci, 2010 . 55(1): 60-5 .
  43. Carvi fructus, ESCOP monographs 2003.
  44. Catassi, G ., E . Lionetti, S . Gatti and C . Catassi "The Low FODMAP Diet: Many Question Marks for a Catchy Acronym ." Nutrients, 2017 . 9(3): 292 .
  45. Company Core Data Sheet Iberogast®, Version 03 from Nov, 2 2018 .
  46. Csef, H . “Funktionelle (somatoforme) Störungen beim internistischen Hausbesuch .” Internist, 2001 . 42: 1476 .
  47. De Giorgio, R ., U . Volta and P . R . Gibson "Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?" Gut, 2016 . 65(1): 169-78 .
  48. Deding, U ., C . Torp-Pedersen and H . Bøggild "Perceived stress as a risk factor for dyspepsia: a register-based cohort study ." Eur Gastroenterol Hepatol, 2017 . 29(5): 560-567 .
  49. Deng, Y ., B . Misselwitz, N . Dai and M . Fox "Lactose Intolerance in Adults: Biological Mechanism and Dietary Management ." Nutrients, 2015 . 7(9): 8020-35 .
  50. Drossman, D . A . and W . L . Hasler “Rome IV-Functional GI Disorders: Disorders of GutBrain Interaction .” Gastroenterology, 2016 . 150(6): 1257–1261 .
  51. Drossman, D . A ., L . Chang, S . Schneck, C . Blackman, W . F . Norton and N . J . Norton "A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity ." Dig Dis SCi, 2009 . 54(7): 1532-41 .
  52. El-Ghazaly, M . A ., R . M . El-Hazek and M . T . Khayyal "Protective effect of the herbal preparation, STW 5, against intestinal damage induced by gamma radiation in rats" Int J Radiat Biol, 2015 . 91 (2): 150-6 .
  53. Enck, P ., F . Azpiroz, G . Boeckxstaens, S . Elsenbruch, C . Feinle-Bisset, G . Holtmann, J . M . Lackner, J . Ronkainen, M . Schemann, A . Stengel, J . Tack, S . Zipfel and N . J . Talley “Functional dyspepsia .” Nat Rev Dis Primers, 2017 . 3: 17081 .
  54. Enck, P ., Q . Aziz, G . Barbara, A . D . Farmer, S . Fukudo, E . A . Mayer, B . Niesler, E . M . Quigley, M . Rajilic-Stojanovic, M . Schemann, J . Schwille-Kiuntke, M . Simren, S . Zipfel and R . C . Spiller “Irritable bowel syndrome .” Nat Rev Dis Primers, 2016 . 2: 16014 .
  55. European Medicines Agency: EMEA/HMPC/263293/2006 - "Assessment repot on Foeniculum vulgare Miller subsp. vulgare Var. dulce (miller) Thellung, fructus ." Published 16 February 2010 . Available from: https://www.ema.europa.eu/en/documents/herbal-summary/foeniculum-vulgare-miller-subsp-vulgare-var-dulce-miller-thellung-fructus-fennel-fruit-sweet-hmpc_en.pdf .
  56. European Medicines Agency: EMA/HMPC/196746/2012 – “Assessment report on Melissa officinalis L ., folium .” Published 14 May 2013 . Available from: https://www .ema .europa .eu/documents/ herbal-report/final-assessment-report-melissa-officinalis-l-folium_en .pdf .
  57. European Medicines Agency: EMA/HMPC/294188/2013 – “Assessment report on Silybum marianum (L .) Gaertn ., fructus .” Published 5 June 2018 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-silybum-marianum-l-gaertn-fructus_en .pdf .
  58. European Medicines Agency: EMA/HMPC/369801/2009 – “Assessment report on Chelidonium majus L ., herba .” Published 13 September 2011 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-chelidonium-majus-l-herba_en .pdf .
  59. European Medicines Agency: EMA/HMPC/55837/2011 – “Assessment report on Matricaria recutita L ., flos and Matricaria recutita L ., aetheroleum .” Published 1 July 2014 . Available from: https:// www .ema .europa .eu/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flosmatricaria-recutita-l-aetheroleum_en .pdf .
  60. European Medicines Agency: EMA/HMPC/571122/2010 Corr . – “Assessment report on Glycyrrhiza glabra L . and/or Glycyrrhiza inflata Bat . and/or Glycyrrhiza uralensis Fisch ., radix .” Published 12 March 2013 . Available from: https://www .ema .europa .eu/documents/herbal-report/final-assessmentreport-glycyrrhiza-glabra-l/glycyrrhiza-inflata-bat/glycyrrhiza-uralensis-fisch-radix_en .pdf .
  61. European Medicines Agency: EMA/HMPC/614586/2012 – “Assessment report on Angelica sinensis (Oliv .) Diels, radix .” Published 9 July 2013 . Available from: https://www .ema .europa .eu/ documents/herbal-report/final-assessment-report-angelica-sinensis-oliv-diels-radix-first-version_en .pdf .
  62. European Medicines Agency: EMA/HMPC/715092/2013 – “European Union herbal monograph on Carum carvi L ., fructus .” Published 14 November 2014 . Available from: https://www .ema . europa .eu/documents/herbal-monograph/draft-european-union-herbal-monograph-carum-carvi-lfructus_en .pdf .
  63. European Medicines Agency: EMEA/HMPC/193910/2007 – “Assessment report on Mentha X piperita L ., folium .” Published 4 September 2008 . Available from: https://www .ema .europa .eu/documents/ herbal-report/assessment-report-mentha-x-piperita-l-folium_en .pdf .
  64. European Medicines Agency: EMEA/HMPC/246816/2005 – “Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin .” Published 20 February 2006 . Available from: https://www .ema .europa .eu/documents/scientific-guideline/guideline-good-agriculturalcollection-practice-gacp-starting-materials-herbal-origin_en .pdf .
  65. Feinle-Bisset C . and F . Azpiroz "Dietary and lifestyle factors in functional dyspepsia ." Nat Rev Gastroenterol Hepatol, 2013 . 10(3): 150-7 .
  66. Filipović, B . F ., T . Randjelovic, N . Kovacevic, N . Milinić, O . Markovic, M . Gajić, B . R . Filipović "Laboratory parameters and nutritional status in patients with functional dyspepsia ." Eur J Intern Med, 2011 . 22(3): 300-4 .
  67. Flos Chamomillae, WHO monograph 2010.
  68. Folium Melissae, WHO monograph 2010.
  69. Folium Menthae Piperitae, WHO monograph 2002.
  70. Fond. G ., A . Loundou, N . Hamdani, W . Boukouaci, A . Dargel, J . Oliveira, M . Roger, R . Tamouza, M . Leboyer and L . Boyer "Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis ." Eur Arch Pyschiatry Clin Neurosci, 2014 . 264(8): 651-60 .
  71. Ford, A . C ., A . Marwaha, R . Sood and P . Moayeddi "Global prevalence of, and risk factors for, univestigated dyspepsia: a meta-analysis ." Gut, 2015 . 64(7): 1049-57 .
  72. Ford, A . C ., P . Moayyedi, B . E . Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel, E . M . M . Quigley "American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation ." Am J Gastroenterol. 2014 . 109 Suppl 1: s2-26; quiz S27 .
  73. Fructus Silybi Mariae, WHO monograph 2002.
  74. Gabrielli, A . , E . V . Avvedimento and T . Krieg "Scleroderma ." N Engl J Med, 2009 . 360(19): 1989-2003 .
  75. Germann, I ., D . Hagelauer, O . Kelber, B . Vinson, S . Laufer, D . Weiser, H . Heinle "Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®)." Phytomedicine, 2006 . 13: p. 45-50.
  76. Ghisa, M ., M . D . Coletta, I . Barbuscio, E . Marabotto, B . Barberio, M . Frazzoni, N . De Bortoli, P . Zentilin, S . Tolone, A . Ottonello, G . Lorenzon, V . Savarino and E . Savarino "Updates in the field of non-esophageal gastroesophageal reflux disorder ." Expert Rev Gastroenterol Hepatol, 2019 . 13(9): 827-838 .
  77. Göktaş, Z ., S . Köklü, D . Dikmen, Ö . Öztürk, B . Yılmaz, M . Asıl, H . Korkmaz, Y . Tuna, M . Kekilli, E . K . Aksoy, H . Köklü, A . Demir, G . Köklü and S . Arslan " Nutritional habits in functional dyspepsia and its subgroups: a comparative study ." Scand J Gastroenterol, 2016 . 51(8): 903-7 .
  78. Gschossmann, J . M ., G . Holtmann and E . A . Mayer “[Epidemiology and clinical phenomenology of visceral pain] .” Schmerz, 2002 . 16(6): 447–451 .
  79. Gundermann, K . J ., E . Godehardt and M . Ulbrich “Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials .” Adv Ther, 2003 . 20(1): 43–49 .
  80. Hachem, C . and N . J . Shaheen "Diagnosis and Management of Functional Heartburn ." Am J Gastroenterol, 2016 . 111(1): 53-61 .
  81. Hagelauer, D ., O . Kelber, D . Weiser, S . Laufer and H . Heinle “Effects of Substance P and Neurotensin on the contractility of ileum of mice in vitro: Inhibition by plant extract STW 5 (Iberogast®) .” Planta Med, 2007 . 73(09): P_478 .
  82. Halmos, E . P ., C . T . Christophersen, A . R . Bird, S . J . Shepherd, P . R . Gibson and J . G . Muir "Diets that differ in their FODMAP content alter the colonic luminal microenvironment ." Gut, 2015 . 64(1): 93-100 .
  83. Halmos, E . P ., V . A . Power, S . J . Shepherd, P . R . Gibson and J . G . Muir "A diet low in FODMAPs reduces symptoms of irritable bowel syndrome ." Gastroenterology, 2014 . 146(1): 67-75 e5 .
  84. Hasler WL, Gas and Bloating, Gastroenterol Hepatol (N Y). 2006 Sep; 2(9): 654–66
  85. Hassanzadeh, S ., P . Saneei, A . H . Keshteli, H . Daghaghzadeh, A . Esmaillzadeh and P . Adibi "Meal frequency in relation to prevalence of functional dyspepsia among Iranian adults ." Nutrition, 2016 . 32(2): 242-8 .
  86. Hayes, P . A ., M . H . Fraher and E . M . M . Quigley "Irritable bowel syndrome: the role of food in pathogenesis and management ." Gastroenterol Hepatol (N Y), 2014 . 10(3): 164-74 .
  87. Herba Chelidonii, WHO monograph 2010.
  88. Hohenester, B ., A . Rühl, O . Kelber and M . Schemann “The herbal preparation STW5 (lberogast) has potent and region-specific effects on gastric motility .” Neurogastroenterol Motil, 2004 . 16(6): 765–773 .
  89. Hölscher, H. J. "Therapy of Non-specific Gastrointestinal Complaints in Elderly Patients" Therapiwoche, 1984 . 34: 657-659 .
  90. Holtmann, G ., A . Shah and M . Morrison “Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview .” Dig Dis, 2017 . 35 (Suppl 1): 5–13 .
  91. Holtmann, G ., D . Schrenk, A . Madisch, H . D . Allescher, G . Ulrich-Merzenich, F . Mearin, D . Larrey and P . Malfertheiner "Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Dirsorders: A conceptional Framework for Risk-Benefit Assessment and Regulatory approaches " Dig Dis, 2019 . online, DOI: 10.1159/000504570
  92. Holtmann, G ., N. J. Talley "Herbal medicines for the treatment of functional and inflammatory bowel disorders ." Clinical Gastroenterol Hepatol, 2015 . 13(3): 422-32.
  93. Houghton, L . A ., M . Heitkemper, M . Crowell, A . Emmanuel, A . Halpert, J . A . McRoberts and B . Toner “Age, Gender and Women's Health and the Patient .” Gastroenterology, 2016 . 150(6): 1332–1343 .e1334 .
  94. Iberis, Hager ROM 2003, Springer Verlag, Heidelberg 2003, HN: 2001400.
  95. Illing, G ., G . Sajthy "On the Antiemetic Effect of Iberogast® " Der Kassenarzt, 1984 . 24: 46-49 .
  96. Iovino, P ., C . Bucci, F . Tremolaterra, A . Santonicola and G . Chiarioni “Bloating and functional gastro-intestinal disorders: where are we and where are we going?” World J Gastroenterol, 2014 . 20(39): 14407–14419 .
  97. Jones, H . F ., R . N . Butler and D . A . Brooks "Intestinal dructose transport and malabsorption in humans ." Am J Physiol Gastrointest Liver Physiol, 2010 . 300: G202-G206 .
  98. Kelber, O ., B . Steinhoff, C . Nauert, A . Biller, M . Adler, H . Abdel-Aziz, S . N . Okpanyi, K . Kraft and K . Nieber “Ethanol in herbal medicinal products for children: Data from pediatric studies and pharmacovigilance programs .” Wien Med Wochenschr, 2017 . 167(7–8): 183–188 .
  99. Khayyal, M . T ., M . A . el-Ghazaly, S . A . Kenawy, M . Seif-el-Nasr, L . G . Mahran, Y . A . Kafafi and S . N . Okpanyi “Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination .” Arzneimittelforschung, 2001 . 51(7): 545–553 .
  100. Khayyal, M . T ., M . Abdel-Tawab, S . El-Sayed, B . Vinson and A . Abdel-Aziz "Effect of the herbal preparation, STW 5, on the microbiome in an experimental model of functional dyspepsia " Gastroenterology, 2017 . 152 (5): S1009 .
  101. Khayyal, M . T ., M . Seif-El-Nasr, M . A . El-Ghazaly, S . N . Okpanyi, O . Kelber and D . Weiser “Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast®) and its components against ulcers and rebound acidity .” Phytomedicine, 2006 . 13 (Suppl 5): 56–66 .
  102. Klein-Galczinsky, C . and I . Sassin “P25: Post-marketing surveillance of the efficacy and tolerability of Iberogast® for the therapy of colon irritabile .” German Soc Phytoth, 1999 . p 125 .
  103. Koduru, P ., M . Irani and E . M . M . Quigley "Definition, Pathogenesis, and Management of That Cursed Dyspepsia ." Clin Gastroenterol Hepatol, 2018 . 16(4): 467-479 .
  104. Kohlhoff, E ., U . Hübner-Steiner "Controlled Double-blind Study of Iberogast® versus Placebo in the Treatment of Gastrointestinal Ailments due to Stress at the Workplace", Internal Study report: 8: Research Report No. 06/85 1-55 .
  105. Kroll, U ., C . Cordes "Pharmaceutical prequisites for a multi-target therapy ." Phytomedicine, 2006 . 13: 12-19 .
  106. Lacy, B . E ., F . Mearin, L . Chang, W . D . Chey, A . J . Lembo, M . Simren and R . Spiller “Bowel Disorders .” Gastroenterology, 2016 . 150(6): 1393–1407 .e1395 .
  107. Lebwohl, B ., D . S . Sanders and P . H . R . Green "Coeliac disease ." Lancet, 2018 . 391(10115): 70-81 .
  108. Lindkvist, B . "Diagnosis and treatment of pancreatic exocrine insufficiency ." World J Gastroenterol, 2013 . 19(42): 7258-66 .
  109. Liquiritiae radix, ESCOP monographs 2003.
  110. Liu, C .-Y ., M . H . Müller, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine .” Neurogastroenterology & Motility, 2004 . 16(6): 759–764 .
  111. Lovell, R . M . and A . C . Ford “Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis .” Clin Gastroenterol Hepatol, 2012 . 10(7):712–721 .e4 .
  112. MacLean, N., U . Hübner-Steiner "Controlled Double-Blind Study of Iberogast® verus Placebo for the Treatment of Gastrointestinal Complaints due to Drug Intolerance", Internal Study Report 7: Research Report No. 07/85 1-61 .
  113. MacLean, N., U. Hübner-Steiner "Controlled Double-Blind Study of Iberogast® versus Placebo for the Treatment of Gastrointestinal Complaints due to Drug Intolerance", Internal Study Report 6: Research Report No. 06/86 1-49 .
  114. Madisch, A ., G . Holtmann, K . Plein and J . Hotz “Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial .” Aliment Pharmacol Ther, 2004 . 19(3): 271–279 .
  115. Madisch, A ., H . Melderis, G . Mayr, I . Sassin and J . Hotz “Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie .” Z Gastroenterol, 2001 . 39(07): 511–517 .
  116. Malfertheiner, P . "STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders ." Dig Dis, 2017 . 35: 25-29.
  117. Manuyakorn, W . and P . Tanpowpong "Cow milk protein allergy and other common food allergies and intolerances ." Paediatr Int Child Health, 2019 . 39(1): 32-40 .
  118. Marx, L ., D . Grundmann, S . Dominik, M . Klotz, D . Simon, H . Rabe, H . Abdel-Aziz, O . Kelber and K .-H . Schäfer “Influences of STW 5, a multi-component herbal preparation, on motility and inflammation challenges in gut and enteric nervous system (ENS) .” Digestive Disease Week 2016 . San Diego Convention Center, 2016 .
  119. Marzio, L ., M . Falcucci, L . Grossi, F . A . Ciccaglione, M . G . Malatesta, A . Castellano and E . Ballone “Proximal and distal gastric distension in normal subjects and H . pylori-positive and -negative dyspeptic patients and correlation with symptoms .” Dig Dis Sci, 1998 . 43(12): 2757–2763 .
  120. Matricariae flos, ESCOP monographs 2003.
  121. Mayer, E . A ., S . Bradesi, L . Chang, B . M . R . Spiegel. J . A . Bueller and B . D . Naliboff "Functional GI disorders: from animal models to drug development ." Gut, 2008 . 57(3): 384-404 .
  122. Melissae folium, ESCOP monographs 2013.
  123. Melzer, J ., W . Rosch, J . Reichling, R . Brignoli and R . Saller “Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast®) .” Aliment Pharmacol Ther, 2004 . 20(11-12): 1279–1287 .
  124. Menthae piperitae folium, ESCOP monographs 2019.
  125. Metz, A . and G . Hebbard "Nausea and vomiting in adults--a diagnostic approach ." Aust Fam Physician, 2007 . 36(9): 688-92 .
  126. Michael, S ., H . Abdel-Aziz, D . Weiser, C . E . Muller, O . Kelber and K . Nieber “Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations .” Naunyn Schmiedebergs Arch Pharmacol, 2012 . 385(4): 411–421 .
  127. Michael, S ., O . Kelber, S . Hauschildt, K . divel-Borowski and K . Nieber “Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6 .” Phytomedicine, 2009 . 16(2-3): 161–171 .
  128. Michaudet, C . and J . Malaty "Chronic Cough: Evaluation and Management ." Am Fam Physician, 2017 . 96(9): 575-580 .
  129. Moayyedi, P ., E . M . M . Quigley, B . E. Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel and A . C . Ford "The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis ." Am J Gastroenterol, 2014 . 109(9): 1367-74 .
  130. Mueller, M . H ., H . Seeliger, N . Hering, M . S . Kasparek, A . H . Abdel and M . E . Kreis “Differential Desensitisation of Afferent Nerve Fibres by Iberis amara (STW 6) and Iberogast® (STW 5) in the Murine Colon .” Am J Phytomed Clin Ther, 2018 . 6(1:4) .
  131. Mullan, A ., P . Kavanagh, P . O'Mahony, T . Joy, F . Gleeson and M . J . Gibney "Food and nutrient intakes and eating patterns in functional and organic dyspepsia ." Eur J Clin Nutr, 1994 . 48(2): 97-105 .
  132. Müller, M . H ., C . Y . Liu, J . Glatzle, D . Weiser, O . Kelber, P . Enck, D . Grundy and M . E . Kreis “STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine .” Phytomedicine, 2006 . 13 (Suppl 5): 100–106 .
  133. Ness-Jensen, E ., K . Hveem, H . El-Serag and J . Lagergren "Lifestyle Intervention in Gastroesophageal Reflux Disease ." Clin Gastroenterol Hepatol, 2016 . 14(2): 175-82.e1-3 .
  134. Nicolay, K . "Metoclopramide versus the Herbal Medicine Iberogast® in the Treatment of Functional Gastroenteropathies" Gastro-Entero-Hepatologie, 1984. 2:1-12.
  135. Nieber, K ., V . Winkelmann, S . Hoser, O . Kelber, H . Abdel-Aziz and D . Weiser “Evaluation of the cytoprotective effects of individual and combined constituents of the herbal drug STW 5 .” Planta Medica, 2012 . 78(11):1086
  136. Ohms, P . "Tablets Every Day: How Long can the Stomach Tolerate it? " Ärztl. Praxis, 1983 . 35: 3109-3110.
  137. Okpanyi, S . N . “Acute oral toxicity of Iberogast® (STW 5) in the rat .” 1986 . STW FB 17/86 .
  138. Okpanyi, S . N . “Acute oral toxicity of Iberogast® in the mouse .” 1986 . STW FB 18/86 .
  139. Ottilinger, B ., M . Storr, P . Malfertheiner, H . D . Allescher "STW 5 (Iberogast® -- a safe and effective standard in the treatment of functional gastrointestinal disorders ." Wien Med Wochenschr, 2013. 163(3-4): 65-72 .
  140. Patti, M . G ., H . I . Goldberg, M . Arcerito, L . Bortolasi, J . Tong and L . W . Way "Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury ." Am J Surg, 1996 . 171(1): 182-6 .
  141. Pilichiewicz, A . N ., M . Horowitz, A . Russo, A . F . Maddox, K . L . Jones, M . Schemann, G . Holtmann and C . Feinle-Bisset “Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men .” Am J Gastroenterol, 2007 . 102(6): 1276–1283 .
  142. Radix Glycyrrhizae, WHO monograph 2010.
  143. Raedsch, R ., B . Vinson, B . Ottillinger and G . Holtmann “Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders: A noninterventional study with Iberogast® .” Wien Med Wochenschr, 2018 . 168(3–4): 89–98 .
  144. Raedsch, R ., J . Hanisch, P . Bock, A . Sibaev, B . Vinson and K . J . Gundermann “Wirksamkeit und Unbedenklichkeit des Phytopharmakons STW 5 versus Metoclopramid bei funktioneller Dyspepsie unter Praxisbedingungen - eine retrolektive Kohortenstudie .” Z Gastroenterol, 2007 . 45(10): 1041–1048 .
  145. Rajindrajith, S ., J . Zeevenhooven, N . M . Devanarayana, B . J . C . Perera and M . A . Benninga "Functional abdominal pain disorders in children ." Expert Rev Gastroenterol Hepatol, 2018 . 12(4): 369-390 .
  146. Rasmussen, S ., T . H . Jensen, S . L . Henriksen, P . F . Haastrup, P . V . Larsen, J . Sondergaard and D . E . Jarbol “Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population .” Scand J Gastroenterol, 2015 . 50(2): 162–169 .
  147. Reichling, J . and R . Saller “Iberis amara L . (Bittere Schleifenblume) – Profil einer Heilpflanze .” Forsch Komplementärmed Klass Naturheilkd, 2002 . 9: 21–33 .
  148. Richter, J . E . "Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications ." Am J Gastroenterol, 2000 . 95(2): 368-73 .
  149. Rösch, W ., B . Vinson and I . Sassin “A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia .” Z Gastroenterol, 2002 . 40(6): 401–408 .
  150. Saito, Y . A ., G . M . Petersen, J . J . Larson, E . J . Atkinson, B . L . Fridley, M . de Andrade, G . R . Locke 3rd, J . M . Zimmerman, A . E . Almazar-Elder and N . J . Talley "Familial aggregation of irritable bowel syndrome: a family case-control study ." Am J Gastroenterol, 2010 . 195(4): 833-41 .
  151. Sassin, I . and D . Buchert “Efficacy and tolerability of the herbal prepararion Iberogast® in the therapy of Functional Dyspepsia .” Phytomedicine, 2000 . 7(Suppl . II): 91–92 .
  152. Schemann, M ., K . Michel, F . Zeller, B . Hohenester and A . Ruhl “Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum .” Phytomedicine, 2006 . 13 (Suppl 5): 90–99 .
  153. Schempp, H ., A . Toth, D . Weiser, E . F . Elstner "Antioxidative properties of Iberis amara extracts in biochemical model reactions ." Arzneimittelforschung, 2003 . 13677247
  154. Schempp, H ., D . Weiser, O . Kelber and O . Elstner "Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast®) and its components ," Phytomedicine, 2006 . 13 Suppl 5:36-44 .
  155. Schempp, H ., S . Hippeli, D . Weiser, O . Kelber, E . F . Elstner "Comparison of the inhibition of myeloperoxidase-catalyzed hypochlorite formation in vitro and in whole blood by different plant extracts contained in a phytopharmacon treating functional dyspepsia ." Arzneimittelforschung, 2004 . 54(7):389-95 .
  156. Schiller, L . R . "Maldigestion Versus Malabsorption in the Elderly ." Curr Gastroenterol Rep, 2020 . 22(7): 33 .
  157. Schneider, M ., T . Efferth and H . Abdel-Aziz “Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells .” Front Pharmacol, 2016 . 7: 393 .
  158. Schoenmakers A . C . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): Combined 3 and 6-month oral gavage toxicity study in male and female Wistar rats followed by a one-month recovery period .” 2003 . Notox project no . 330211 .
  159. Sibaev, A ., H . Abdel-Aziz, O . Kelber, H . D . Allescher and M . Storr “Mechanism of action of STW 5 and its components on motility and intestinal neurotransmission in “in vitro” model of the human colon .” Neurogastroenterol Motil, 2015 . 27 (Suppl . 2): 101 .
  160. Sierra, D ., M . Wood, S . Kolli and L . M . Felipez "Pediatric Gastritis, Gastropathy, and Peptic Ulcer Disease ." Pediatr Rev, 2018 . 39(11): 542-549 .
  161. Silybi mariani fructus, ESCOP monographs 2009.
  162. Simmen, U ., O . Kelber, R . Jaeggi, B . Büter, S . N . Okpanyi and D . Weiser . “Relevance of the herbal combination of STW 5 for its binding affinity to the muscarinic M3 receptor .” Naunyn Schmiedeberg´s Arch Pharmacol, 2003 . 367, (Suppl 1): R22 .
  163. Simmen, U ., O . Kelber, S . N . Okpanyi, R . Jaeggi, B . Bueter and D . Weiser “Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors .” Phytomedicine, 2006 . 13: 51–55 .
  164. Sporrer, M . "Rapidly Effective Phytotherapy in Gastrointestinal Complaints " Medica - Seminarzeitschrift für die ärztliche Praxis, 1984 . 5
  165. Stanghellini, V ., F . De Ponti, R . De Giorgio, G . Barbara, C . Tosetti and R . Corinaldesi “New developments in the treatment of functional dyspepsia .” Drugs, 2003 . 63(9): 869–892 .
  166. Stanghellini, V ., F . K . Chan, W . L . Hasler, J . R . Malagelada, H . Suzuki, J . Tack and N . J . Talley “Gastroduodenal Disorders .” Gastroenterology, 2016 . 150(6): 1380–1392 .
  167. Steimer, P . "Iberogast® Therapy in Gastroenterology - Therapeutic Experience Report ." Der Krankenhausarzt, 1983. Vol. 12: 1005-1008 .
  168. Surdea-Blaga, T ., D . E . Negrutiu, M . Palage and D . L . Dumitrascu "Food and Gastroesophageal Reflux Disease ." Curr Med Chem, 2019 . 26(19): 3497-3511 .
  169. Tack, J ., H . Piessevaux, B . Coulie, P . Caenepeel and J . Janssens “Role of impaired gastric accommodation to a meal in functional dyspepsia .” Gastroenterology, 1998 . 115(6): 1346–1352 .
  170. Tack, J ., I . Demedts, G . Dehondt, P . Caenepeel, B . Fischler, M . Zandecki and J . Janssens “Clinical and pathophysiological characteristics of acute-onset functional dyspepsia .” Gastroenterology, 2002 . 122(7): 1738–1747 .
  171. Tack, J ., P . Caenepeel, B . Fischler, H . Piessevaux and J . Janssens “Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia .” Gastroenterology, 2001 . 121(3): 526–535 .
  172. Talley, N . J . and A . C . Ford "Functional Dyspepsia ." N Engl J Med, 2015 . 373(19): 1853-63 .
  173. Talley, N . J ., M . M . Walker and G . Holtmann “Functional dyspepsia .” Curr Opin Gastroenterol, 2016 . 32(6): 467–473 .
  174. Thélin, C . S . and J . E . Richter "Review article: the management of heartburn during pregnancy and lactation ." Aliment Pharmacol Ther, 2020 . 51(4): 421-434 .
  175. Thumshirn, M . “Pathophysiology of functional dyspepsia .” Gut, 2002 . 51 (Suppl 1): i63-66 .
  176. Tullmann, D . F . and K . Dracup "Knowledge of heart attack symptoms in older men and women at risk for acute myocardial infarction ." J Cardiopulm Rehabil, 2005 . 25(1): 33-9 .
  177. Ulrich-Merzenich, G ., L. Welslau, H. Aziz-Kalbhenn, O. Kelber, A. Shcherbakova "Synergy quantifications to identify individual contributions of combination partners to the overall activity - The example of STW 5 ." Phytomedicine, 2019. 16: 153013 .
  178. Van Oudenhove, L . and Q . Aziz "The role of psychosocial factors and psychiatric disorders in functional dyspepsia ." Nat Rev Gastroenterol Hepatol, 2013 . 10(3): 158-67 .
  179. van Rozendaal, A . W . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): 3-Month oral gavage toxicity study in male and female Beagle dogs followed by a 1-month recovery period .” 2003, Notox project no . 330222 .
  180. van Rozendaal, A . W . M ., W . J . A . M . Frieling and C . J . Mitchell “STW 5 (Iberogast®): Acute oral toxicity study in male and female Wistar rats .” 2003, Notox project no . 320265 .
  181. Vazquez-Roque, M . I ., M . Camilleri, T . Smyrk, J . A . Murray, E . Marietta, J . O'Neill, P . Carlson, J . Lamsam, D . Janzow, D . Eckert, D . Burton and A . R . Zinsmeister "A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function ." Gastroenterology, 2013 . 144(5): 903-911 e3 .
  182. Vinson, B . and G . Holtmann “Mo1885 A Survey of Treatment of Patients With Functional Dyspepsia in the Routine Clinical Setting .” Gastroenterology, 2013 . 144(5): S–683 .
  183. Vinson, B . and M . Radke “The herbal preparation STW 5 for the treatment of functional gastrointestinal diseases in children aged 3–14 years – a prospective non interventional study .” Digestive disease week, Chicago, IL, USA ., 2011 . Abstract #523 .
  184. Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “In vivo/in vitro unscheduled DNA synthesis in rat hepatocytes with STW 5 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/ Germany, Test Report 1996 . CCR project no: 538203 .
  185. Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “Micronucleus assay in bone marrow cells of the mouse with STW 5 . Test report, Proj . No . 538 204 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/Germany, Test Report 1996 . CCR project no: 538104 .
  186. Völkner, W ., M . Arenz, F . Hermann and H . G . Miltenburger “Micronucleus assay in bone marrow cells of the mouse with STW 5 .” CCR Cytotest Cell Research GmbH & Co . KG, Roßdorf/Germany . Test Report 1996 . CCR project no: 538204 .
  187. von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study .” Am J Gastroenterol, 2007 . 102(6): 1268–1275 .
  188. Voß, U ., F . Herr, N . Störmer, S . Okpanyi, D . Weiser, O . Kelber, H . Abdel-Aziz and K . Nieber, “Effects of STW 5, STW 5II and their components on contractility of inflamed rat colon preparations .” Young Researchers Meeting . Münster, 2012 .
  189. Wadie, W ., H . Abdel-Aziz, H . F . Zaki, O . Kelber, D . Weiser and M . T . Khayyal “STW 5 is effective in dextran sulfate sodium-induced colitis in rats .” Int J Colorectal Dis, 2012 . 27(11): 1445–1453 .
  190. Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomed, 2006 . 13 SV 122-129
  191. Wagner, H . "Multitarget therapy - The future of treatment for more than just functional dyspepsia ." Phytomedicine, 2006 . 5: 122-9 .
  192. Wald, K ., O . Kelber, D . Weiser, S . Laufer, H . Heinle "Antioxidant properties of STW 5 and its single extracts on histamine-induced radical production of murine ileum ." Z Phytother, 2009 . 30(Suppl. 1): p. S36.
  193. Wallace, J . L . "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?" Physiol Rev, 2008 . 88(4): 1547-65 .
  194. Wang, Y . P ., C . C . Herndon and C . L . Lu "Non-pharmacological Approach in the Management of Functional Dyspepsia ." J Neurogastroenterol Motil, 2020 . 26(1): 6-15 .
  195. Wingate, D ., M . Hongo, J . Kellow, G . Lindberg and A . Smout “Disorders of gastrointestinal motility: towards a new classification .” J Gastroenterol Hepatol, 2002 . 17 (Suppl): S1-14 .
  196. Wong, Y ., D . M . H . Freeland, K . C . Nadeau "Food allergy: immune mechanisms, diagnosis and immunotherapy ." Nat Rev Immunol, 2016 . 16(12): 751-765 .
  197. Yu, H . X ., C . S . Han, J . R . Xue, Z . F . Han and H . Xin "Esophageal hiatal hernia: risk, diagnosis and management ." Expert Rev Gastroenterol Hepatol, 2018 . 12(4): 319-329 .
  198. Zhou, C ., E . Zhao, Y . Li, Y . Jia and F . Li "Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials ." Neurogastroenterol Motil, 2019 . 31(2):e13461 .
  199. Baj, A ., E . Moro, M . Bistoletti, V . Orlandi, F . Crema and C . Giaroni "Glutamergic Signaling Along The Microbiota-Gut-Brain Axis ." Int J Mol Sci, 2019 . 20(6): 1482 .
  200. Berthoud, H . R . and W . L . Neuhuber "Functional and chemical anatomy of the afferenet vagal system ." Auton Neruosci, 2000 . 85(1-3): 1-17 .
  201. Berthoud, H . R . and W . L . Neuhuber "Functional and chemical anatomy of the afferenet vagal system ." Auton Neruosci, 2000 . 85(1-3): 1-17 .
  202. Bonaz, B ., T . Bazin and S . Pellissier "The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis" Front Neurosci, 2018 . 12:49 . 
  203. Bonaz, B ., T . Bazin and S . Pellissier "The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis" Front Neurosci, 2018 . 12:49 . 
  204. Bonfrate, L ., D . M . Di Palo, G . Celano, A . Albert, P . Vitellio, M . De Angelis, M . Gobbetti and P . Portincasa "Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients ." Eur J Clin Invest, 2020 . 50(3):e13201 .
  205. Clifton, P . M . and J . B . Keogh "  A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease ." Nutr Metab Cardiovasc Dis, 2017 . 27(12): 1060-1080 . 87
  206. Coffey, R . J ., M . K . Washington, C . L . Corless and M . C . Heinrich "Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach ." J Clin Invest, 2007 . 117(1): 70-80 . 104
  207. Dinan, T . G . and J . D . Cryan "The Microbiome-Gut-Brain Axis in Health and Disease ." Gastroenterol Clin N Am, 2017 . 46: 77-89 . 45
  208. Ducarmon, Q . R ., R . D . Zwittink, B . V . H . Hornung, W . van Schaik, V . B . Young and E . J . Kuijper "Gut Micorbiota and Colonization Resistance against Bacterial Enteric Infection ." Microbiol Mol Biol Rev, 2019 . 83 (3): e00007-19 . 106
  209. European Medicines Agency: EMA/HMPC/55837/2011 – “Assessment report on Matricaria recutita L ., flos and Matricaria recutita L ., aetheroleum .” Published 1 July 2014 . Available from: https:// www .ema .europa .eu/documents/herbal-report/draft-assessment-report-matricaria-recutita-l-flosmatricaria-recutita-l-aetheroleum_en .pdf . 92
  210. Ford, A . C ., E . M . M . Quigley, B . E . Lacy, A . J . Lembo, Y . A . Saito, L . R . Schiller, E . E . Soffer, B . M . R . Spiegel and P . Moayyedi "Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis ." Am J Gastroenterol, 2014 . 109(10): 1546, 1562 . 69
  211. Fujiwara, Y ., M . Kubo, Y . Kohata, H . Machida, H . Okazaki, H . Yamagami, T . Tanigawa, K . Watanabe, T . Watanabe, K . Tominaga and T . Arakawa "Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome ." Intern Med. 2011 . 50(21): 2443-7 . 98
  212. Furness, J . B . "The enteric nervous system and neurogastroenterology" Nat Rev Gastroenterol Hepatol, 2012 . 9: 286-294 . 7
  213. Galland, L . "The Gut Microbiome and the Brain ." Journal of Medicinal Food, 2017 . 12: 1261-1272 . 105
  214. Giannelli, F . R . "Antibiotic-associated diarrhea ." JAAPA, 2017. 30(10): 46-47 . 64
  215. Guandalini, S . "Probiotics for prevention and treatment of diarrhea ." J Clin Gastroenterol, 2011 . 45 Suppl: S149-53 . 83
  216. Holscher, H . D . "Dietary fiber and prebiotics and the gastrointestinal microbiota ." Gut Microbes, 2017 . 8(2): 172-184 . 81
  217. Hosseinpour, M . and A . Behdad "Evaluation of small bowel measurement in alive patients ." Surgical and Radiologic Anatomy, 2008 . 30, 653-655 . 2
  218. Jenkins, T . A ., J . C . D . Nguyen, K . E . Polglaze and P . B . Bertrand "Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis." Nutrients, 2016 . 8(1): 56 . 111
  219. Kapitan, M ., M . J . Niemiec, A . Steimle, J . S . Frick and I . D . Jacobsen " Fungi as Part of the Microbiota and Interactions with Intestinal Bacteria ." Curr Top Microbiol Immunol, 2019 . 422: 265-301 . 58
  220. Karling, P ., K . F . Norrback, R . Adolfsson and A . Danielsson " Gastrointestinal symptoms are associated with hypothalamic-pituitary-adrenal axis suppression in healthy individuals ." Scand J Gastroenterol, 2007 . 42 (11): 1294-301 . 35
  221. Leung, P . S . "Overview of the Pancreas ." In: The Renin-Angiotensin System: Current Research Progress Progress in The Pancreas. Advances in Experimental Medicine and Biology, 2018 . Volume 690, Springer, Dordrecht, pp 3-12 . 5
  222. Löhr, J . M ., N . Panic, M . Vujasinovic and C . S . Verbeke "The ageing pancreas: a systematic review of the evidence and analysis of the consequences ." J Intern Med, 2018 . 283(5) : 446- 460 . 6
  223. Lozupone, C . A ., J . I. Stombaugh, J . I . Gordon, J . K . Jansson and R . Knight "Diversity, stability and resilience of the human gut microbiota ." Nature, 2012 . 489 (7415): 220-230 . 107
  224. Lozupone, C . A ., J . I. Stombaugh, J . I . Gordon, J . K . Jansson and R . Knight "Diversity, stability and resilience of the human gut microbiota ." Nature, 2012 . 489 (7415): 220-230 . 59
  225. Lynch, S . V . and O . Pederson "The Human Intestinal Microbiome in Health and Disease ." N Engl J Med, 2016 . 375(24):2369-2379 . 57
  226. Markowiak P . and K . Śliżewska " Effects of Probiotics, Prebiotics, and Synbiotics on Human Health ." Nutrients, 2017 . 9(9): 1021 . 82
  227. McDermott, A . J . and G . B . Huffnagle "The microbiome and regulation of mucosal immunity ." Immunology, 2014 . 142(1): 24-31 . 63
  228. Phillips, M ., A . Patel, P . Meredith, O . Will and C . Brassett " Segmental colonic length and mobility .", Ann R Coll Engl, 2015 . 97(6): 439-44 . 56
  229. Pinto-Sanchez, M . I ., G . B . Hall, K . Ghajar, A . Nardelli, C . Bolino, J . T . Lau, F . P . Martin, O . Cominetti, C . Welsh, A . Rieder, J . Traynor, C . Gregory, G . De Palma, M . Pigrau, A . C . Ford, J . Macri, B . Berger, G . Bergonzelli, M . G . Surette, S . M . Collins, P . Moayyedi and P . Bercik "Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome ." Gastroenterology, 2017 . 153(2): 448-459.e8 . 86
  230. Ricci, C ., J . Holton and D . Vaira "Diagnosis of Helicobacter pylori: invasive and non-invasive tests ." Best Pract Res Clin Gastroenterol, 2007 . 21(2): 299-313 . 101
  231. Rinninella, E ., P . Raoul, M . Cintoni, F . Franceschi, G . A . D . Miggiano, A . Gasbarrini and M . C . Mele "What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet and Diseases ." Microorganisms, 2019 . 7, 14 .Schubert, M . L . and D . A . Peura "Control of gastric acid secretion in health and disease ." Gastroenterology, 2008 . 134(7): 1842-60 .
  232. Rinninella, E ., P . Raoul, M . Cintoni, F . Franceschi, G . A . D . Miggiano, A . Gasbarrini and M . C . Mele "What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet and Diseases ." Microorganisms, 2019 . 7, 14 .
  233. Rooks, M . G . and W . S . Garrett "Gut microbiota, metabolites and host immunity ." Nat Rev Immunol, 2016 . 16(6): 341-352 .
  234. Schneider, S ., C . M . Wright and R . O . Heuckeroth "Unexpected Roles for the Second Brain: Enteric Nverous System as Master Regulator of Bowel Function ." Annual Review of Physiology, 2019 . 81: 235-59 .
  235. Schubert, M . L . and D . A . Peura "Control of gastric acid secretion in health and disease ." Gastroenterology, 2008 . 134(7): 1842-60 .
  236. Sipponen, P . and H . I . Maaroos "Chronic gastritis ." Scand J Gastroenterol, 2015 . 50(6): 657-67 .
  237. Smith, R . P., C. Easson, S . M . Lyle. , R . Kapoor, C . P . Donnelly, E . J . Davidson, E . Parikh, J . V . Lopez and J . L . Tartar "Gut microbiome diversity is associated with sleep physiology in humans ." PLOS ONE, 2019 . 14(10): e0222394 .
  238. Strandwitz, P . "Neurotransmitter modulation by the gut microbiota ." Brain Res, 2018 . 1693 (Pt B): 128-133 .
  239. Thaiss, C . A ., N . Zmora, M . Levy and E . Elinav "The microbiome and innate immunity" Nature, 2016. 535, 65-74 .
  240. Yuan, F ., H . Ni, C . V . Asche, M . Kim, S . Walayat and J . Ren "Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis ." Curr Med Res Opin, 2017 . 33(7): 1191-1197 .
  241. https://www.niddk.nih.gov/health-information/digestive-diseases/digestive-system-how-it-works
  242. Braden Kuo, M.D. and Daniela Urma, M.D.
  243. M. Buunen, P. P. G. M. Rooijens, H. J. Smaal, G. J. Kleinrensink, E. Van Der Harst, H. W. Tilanus, J. F. Lange
  244.  "The human proteome in stomach - The Human Protein Atlas". www.proteinatlas.org. Retrieved 2017-09-25.
  245. Sherif R Z Abdel-Misih 1, Mark Bloomston "Liver anatomy" Surg Clin North Am. Author manuscript; 2014 May 30.
  246. Andrzej Hebzda, Dorota Szczeblowska, Dariusz Serwin, Stanisław Wojtuń, Zbigniew Hebzda, Iwon Grys "Choroba Leśniowskiego-Crohna – diagnostyka i leczenie/ Crohn’s disease – diagnosis and treatment" Published: 31.07.2011
  247. Nagral, Sanjay (2005). "Anatomy relevant to cholecystectomy". Journal of Minimal Access Surgery. 1 (2): 53–8. doi:10.4103/0972-9941.16527. PMC 3004105. PMID 21206646.
  248. https://www.medicalnewstoday.com/articles/319583
  249. https://pulsmedycyny.pl/uchylki-jelita-grubego-choroba-uchylkowa-czesto-przebiega-bezobjawowo-985674
  250. IQVIA, Paragraph, Pharmacy, Gastrointestinal Products, MAT 01/2023

Iberogast®

Zaburzenia ze strony przewodu pokarmowego są zazwyczaj nie tylko wyjątkowo nieprzyjemne i związane z licznymi dolegliwościami, ale często utrudniają codzienne życie. Całe szczęście istnieje Iberogast®: połączenie dziewięciu ziół leczniczych5, 45, 98, 105 skoncentrowane na walce zarówno z podstawowymi przyczynami5, 8, 10, 130, 191 jak i irytującymi objawami23, 28, 45, 79, 114, 115, 123, 149, 187.

Wszystko o Iberogast®

Bibliografia

Iberogast®

Kup Online
Iberogast classic

Przed użyciem zapoznaj się z ulotką, która zawiera wskazania, przeciwwskazania, dane dotyczące działań niepożądanych i dawkowanie oraz informacje dotyczące stosowania produktu leczniczego, bądź skonsultuj się z lekarzem lub farmaceutą, gdyż każdy lek niewłaściwie stosowany zagraża Twojemu życiu lub zdrowiu.

Kobieta trzymająca się za brzuch

Ulga w objawach problemów trawiennych z lekiem Iberogast®

Ziołowe krople Iberogast® działają na różne odcinki układu pokarmowego23, 28, 45, 79, 114, 115, 123, 149 łagodzą objawy problemów trawiennych i są dobrze tolerowane 23, 28, 114, 115, 139, 149, 187.

Dowiedz się więcej
Dwie śmiejące się kobiety

Często zadawane pytania

Znajdź odpowiedzi na najczęściej zadawane pytania o Iberogast®.

Dowiedz się więcej
Iberogast stojący obok szklanki z wodą i wazonu z kwiatkiem

Dowiedz się więcej o leku Iberogast® od firmy Bayer

Połączenie 9 ziół leczniczych5, 45, 98, 105 użytych w leku Iberogast® zostało przebadane i opracowane w późnych latach 50 XX wieku.

Dowiedz się więcej